At a glance
ClinicalIndex Comparison RecordN/ACompleted· 657 enrolled
Drug / intervention
ACRYSOF CACHET Phakic Lens (L-series)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long Term Safety Follow-up for Subjects Previously Implanted With the ACRYSOF® CACHET® Phakic Lens in Clinical Studies C-02-23, C-02-40, C-03-21 and C-05-57
In Brief
A clinical study evaluating ACRYSOF CACHET Phakic Lens (L-series) for Myopia. Completed, enrolled 657 participants across 1 site.
Detailed Summary
The purpose of this long term safety study is to estimate the annualized endothelial cell loss (ECL) rate (for up to 10 years following date of implantation) of subjects previously implanted with the ACRYSOF CACHET Phakic Intraocular Lens (L-series) from precursor clinical studies C-02-23, C-02-40, C-03-21 and C-05-57.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyopia
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2011
First PostedDec 2011
Primary CompletionJun 2018
TodayJul 2026
First PostedDec 22, 2011
Enrollment StartNov 21, 2011
Primary CompletionJun 15, 2018
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 14.5 years ago
Interventions
ACRYSOF CACHET Phakic Lens (L-series)device
Intraocular lens for the treatment of moderate to high myopia